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Abstract 
 
Chromosomal translocations leading to rearrangements of FET family genes (FUS, EWSR1 and TAF15) 
are found in numerous human cancers. These genetic alterations result in the formation of fusion 
oncogenes that express potent chimeric oncoproteins able to promote tumor development. In order to 
further understand the function of the FET genes, we have characterized the expression of their encoded 
proteins products in human tissues and cells. By immunohistochemical analyses, we here demonstrate that 
the FUS, EWS and TAF15 proteins are expressed in a cell type-specific manner in human tissues. In 
experiments using cultured cells, we show that their expression is altered upon differentiation and that 
they localize to stress granules in response to cellular stress. Furthermore, FUS and TAF15 localize to 
spreading initiation centers upon early cell spreading. These results point to multiple cell type-specific 
functions for the FET proteins during both normal and stress conditions. We further attempted to elucidate 
the molecular mechanisms by which the aberrant FUS-DDIT3 protein gives rise to myxoid/round-cell 
liposarcoma (MLS/RCLS), a malignant soft-tissue tumor. FUS-DDIT3 expression results from a 
t(12;16)(q13;p11) translocation that is highly specific for MLS/RCLS and several studies have shown a 
causative role for FUS-DDIT3 in the development of these tumors. In FUS-DDIT3, the N-terminal parts 
of the RNA-binding FUS protein is fused to the entire DDIT3 protein, a transcription factor involved in 
endoplasmatic reticulum stress and programmed cell death. In the context of MLS/RCLS, the chimeric 
FUS-DDIT3 protein acts as an aberrant transcription factor able to deregulate multiple target genes. We 
have previously shown that FUS-DDIT3 and DDIT3 have opposing effects on IL8 transcription in cells 
stably expressing these proteins. Here we demonstrate, by using multiple molecular methods, that FUS-
DDIT3 interacts with the NF-κB system, specifically the NFKBIZ protein, and thereby activates IL8 
expression. These findings propose a role for inflammation-related processes in MLS/RCLS development. 
We further show that the growth factor receptor FLT1 and its ligand PGF are expressed in MLS/RCLS 
cells, which suggests the existence of an intracrine signaling loop in these cells. Moreover, through co-
immunoprecipitation studies, we show that DDIT3 binds cyclin-dependent kinase 2 (CDK2), a protein 
involved in cell cycle regulation. This binding apparently alters the protein affinity of CDK2 and enhances 
its association with components of the cytoskeleton. The involvement of normal FET proteins in multiple 
regulatory pathways within a cell may explain why FET fusion genes are often the sole detectable 
abnormalities in their associated tumors. Specifically, the FUS-DDIT3 gene studied in this thesis can 
promote several of the physical characteristics associated with cancer and thereby drive malignancy. In 
summary, the work included in this thesis suggests that agents which induce cellular differentiation, 
inhibit inflammatory processes (in particular the NF-κB system) or block FLT1 signaling may aid current 
treatments and thereby improve survival of patients afflicted with myxoid liposarcoma. 
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Introduction 
 
1. Cancer 
 
Cancer is a heterogeneous group of diseases characterized by uncontrolled growth 
and spread of abnormal cells. It is the second most common cause of death in the 
Western world and its incidence increases with age. Cancer is currently treated with 
combinations of surgery, radiation, chemotherapy, hormone therapy, biological 
therapy and targeted therapy1.  
 
The majority of cancer forms are associated with the emergence of malignant 
tumors*. These tumors are composed of a mass of abnormal cells that can spread 
out and invade nearby tissue or spawn metastases at distant sites in the body. Most 
human cancers arise from epithelial tissues, which consist of sheets of cells that line 
the walls of cavities and channels, or in the case of skin, serve as outside covering 
of the body. The malignant tumors originating from epithelial tissues are classified 
as carcinomas and these tumors are responsible for more than 80% of the cancer-
related deaths in the West. The remaining malignant tumors arise from 
nonepithelial tissues throughout the body. Sarcomas, which constitute about 1% of 
the malignant tumors encountered in the oncology clinic, derive from tissues 
consisting of mesenchymal cell types. These include muscle, fat, bone, fibrous 
tissue, blood vessels and other tissues supporting the body. Even though rarely 
occuring, sarcomas are life-threatening and often pose a significant diagnostic and 
therapeutic challenge due to their histological heterogeneity. A second group of 
nonepithelial cancers arise in the various cell types that make up the blood-forming 
tissues and in cells of the immune system. These are called leukemias and 
lymphomas respectively. The final group of nonepithelial tumors develops from 
cells that form components of the central and peripheral nervous system. These are 
termed neuroectodermal tumors2. 
 
Carcinogenesis, the development of cancer, is a multistep process that initiates in a 
single normal cell and gradually transforms its progeny into highly malignant 
counterparts3,4. In an exceedingly cited review article from 20005, Hanahan and 
Weinberg propose that six essential alterations in cell physiology are required for 
cancer development: 
                                                 
* Malignant tumors constitute a minority of all human tumors and most tumors are classified as 
benign (localized, noninvasive). Benign tumors are only rarely dangerous to their hosts but may 
in some cases progress to malignant forms if left u
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Self-sufficiency in growth signals 
Normal cells require growth-promoting signals from the extracellular environment before they 
can begin to actively proliferate. No known normal cell type can proliferate in the absence of 
such signals. Tumor cells on the other hand generate many of their own signals, thereby reducing 
their dependence on the normal tissue microenvironment. This ability disrupts one critical 
homeostatic control that preserves a proper behavior of the various cells constituting a tissue in 
the multicellular organism. 
  
Insensitivity to anti-growth signals 
Normal tissue homeostasis is also maintained in large part by antiproliferative signals that induce 
cellular quiescence or differentiation. Tumor cells acquire traits that make them unresponsive to 
such signals, which results in unconstrained proliferation. 
 
Evasion of apoptosis 
The expansion of cells in a tumor depends not only on the rate of proliferation but also on the rate 
of attrition. Programmed cell death, apoptosis, represents a major source of this attrition. A 
normal cell responds to signals of normality or abnormality originating from the extracellular and 
intracellular environment that influence whether it should live or die. Tumor cells gain resistance 
toward such signals and thereby avoid programmed cell death. 
 
Limitless replicative potential 
Most mammalian cells carry an intrinsic program that limits their multiplication and they can not 
divide indefinitely. This program must be disrupted if a cell population is to expand to form a 
macroscopic, life-threatening tumor. 
 
Sustained angiogenesis 
Oxygen and nutrient supply, as well as waste disposal, are crucial for proper cell function and 
survival in tissues. These processes are supported by the vasculature and cells are required to 
reside within 100 µm of a capillary blood vessel to utilize it. The growth of new blood vessels, 
angiogenesis, is carefully regulated in developed tissues and premalignant cells lack angiogenic 
ability, which halt their expansion. Thus, in order to progress to a macroscopically detectable 
size, tumors must obtain the ability to recruit new blood vessels. 
 
Tissue invasion and metastasis 
Eventually, during the development of human cancer, primary tumors spawn pioneer cells that 
gain the ability to move out and invade adjacent tissues or travel to distant sites in the body where 
they may found new colonies. These settlements of tumor cells, metastases, are the cause of 90% 
of human cancer deaths. 
 
Each of the above characteristics, termed the hallmarks of cancer, represent a 
breach of the built-in anticancer defense mechanisms present in normal cells and 
tissues, and are shared by most, if not all, malignant human tumors. The order and 
timescale over which these features are obtained varies between individual tumors. 
So, how do normal cells acquire these capabilities? 
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2. The genetic basis of cancer 
 
In 1890, David von Hansemann concluded, through detailed analysis of carcinoma 
samples, that cancer cells show abnormal mitotic figures*. He proposed that these 
result in an asymmetric distribution of chromosomes to daughter cells following 
cell division6. These findings were further pursued by Theodor Boveri who showed 
that experimentally induced multipolar mitoses in sea-urchin eggs lead to an 
unequal distribution of chromosomes in post-mitotic cells7. Some of the cells die 
from this imbalance while others survive but develop abnormally. From these 
results, Boveri suggested that tumors arise as a consequence of abnormal 
chromosome segregation to daughter cells.  
 
The normal configuration of chromosomes is termed euploid karyotypic state. In 
humans, autosomes are present in 22 normally structured pairs and the X and Y 
chromosomes are present in numbers according to the sex of the individual. Cancer 
cells often differ from this normal configuration, showing presence of extra 
chromosomes or loss of others, in a state termed aneuploidy8. In addition, cancer 
cells generally contain abnormally structured chromosomes with rearrangements 
such as translocations and inversions. Furthermore, segments of a given 
chromosome may be copied many times over and present in multiple copies on a 
given chromosome through a process called amplification. Such segments can also 
exist as separate extrachromosomal entities in the nucleus. On occasion, parts of 
chromosomes are deleted and lost in subsequent cell divisions2. These structural 
rearrangements and changes in chromosome number affect the genes residing in the 
altered chromosomal regions9. 
 
2.1 Oncogenes 
 
The relevance of genetic alterations for cancer development became clear with the 
discovery of the first proto-oncogene src10. This remarkable finding demonstrated 
that genes carried by normal cells have the potential, under certain circumstances, 
to turn into potent oncogenes with the capacity to induce cell transformation and 
thus cancer. Oncogenes invoke one or several of the previously mentioned 
hallmarks of cancer in a dominant manner. Their ability to do so stems from the 
fact that their normal proto-oncogenic counterparts have a range of growth-
promoting functions at the cellular level. These genes encode proteins that act as 
growth factors (e.g. FGF and PDGF), growth factor receptors (e.g. RET and the 
ERBB family), inhibitors of apoptosis (e.g. MDM2 and the BCL2 family), signal 
transducers (e.g. SRC and the RAS family), transcription factors (e.g. MYC and the 
ETS family) and chromatin remodellers (e.g. ALL1). Hence, structural alteration or 
                                                 
* The microscopic appearance of cells undergoing mitosis (somatic cell division). 
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deregulation of expression of such genes can augment normal processes involved in 
cell proliferation and hereby promote malignancy11.  
 
Proto-oncogenes can be converted into oncogenes in several different ways. The 
amplification of chromosomal segments found in some cancer cells often result in 
multiple copies of certain genes being present in the cellular DNA, commonly 
followed by an increase in expression of their encoded proteins12. Translocations, 
i.e. fusions between nonhomologous chromosomes, can also cause oncogene 
activation13 (see section 3). In other cases, a single point mutation* (e.g. affecting a 
critical residue responsible for regulating the activity of the protein product) is all 
that is needed to turn a proto-oncogene into a fully fledged oncogene14.  
 
2.2 Tumor suppressor genes 
 
The discovery of proto-oncogenes provided a simple yet powerful explanation of 
how genetic alterations can fuel the uncontrolled cell proliferation seen in cancer 
cells. However, the underlying logic of any well-functioning control system 
dictates that components that promote a given process must be counterbalanced by 
other components opposing the same process. In the 1970s and early 1980s, 
evidence for the existence of a fundamentally different set of growth-controlling 
genes surfaced15. These tumor suppressor genes (TSGs) operate to constrain or 
suppress cell proliferation. Quite opposite to the case of proto-oncogenes, the 
inactivation or loss of TSGs is associated with tumor development. 
 
The cancer phenotype is recessive at the cellular level16 and in most cases the loss 
of both allelic copies of a tumor suppressor gene is required for a complete 
inactivation of its growth-repressing functions17. The inactivation of a TSG allele 
can occur either through genetic mutations or by epigenetic† silencing18. The 
remaining gene copy can subsequently be lost through different mechanisms 
collectively termed loss of heterozygosity‡ (LOH)19. Repeated LOH events in a 
given chromosomal region in independently arising tumors can indicate the 
presence of a TSG in that region. When a defective copy of a tumor suppressor 
gene is inherited through the germ line, the result is often a greatly increased 
susceptibility to one or another type of cancer and mutant alleles of specific TSGs 
have been found in families with hereditary cancer20. Since mutations in TSG 
alleles are commonly recessive, the loss of a TSG may occur far more frequently 
                                                 
* A nucleobase replacement in DNA (or RNA). 
  
† Chemical modifications of chromatin proteins or DNA bases that do not alter the underlying 
DNA sequence but can result in changes of gene expression. 
 
‡ Loss of heterozygosity can result from gene conversion, deletion, mitotic recombination or 
mitotic nondisjunction. 
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than the activation of a dominant-acting oncogene during both normal and 
neoplastic development. 
 
Tumor suppressor genes regulate cell proliferation through many different 
biochemical mechanisms and they are unified only by the fact that their loss 
increases the likelihood of cancer development. The TP53 gene is lost or mutated in 
approximately half of all human cancers21. Germ line mutations in TP53 predispose 
affected individuals to a wide spectrum of cancers20 and TP53 knockout mice show 
susceptibility to spontaneous tumors22. In the normal case, the p53 protein23,24 is 
transiently stabilized and activated in response to stress, DNA damage and chronic 
mitogenic stimulation. This activation leads to an inhibition of cell cycle 
progression, induction of senescence, differentiation or apoptosis25. Hence, p53 
responds to signals of cellular imbalance and further orchestrates measures to repair 
or eliminate cells that could potentially pose a threat to the organism as a whole. 
Consequently, the loss of normal p53 function puts a cell at risk of accumulating 
cellular damage that could promote cancer development. The first TSG that was 
characterized was the RB1 gene26. Children bearing germ line mutations in this 
gene are predisposed to retinal tumors at a young age and osteosarcomas as 
adolescents. The protein encoded by RB1 governs the progress of a wide variety of 
cells through their growth and division cycles, and the growth control imposed by 
the RB1 circuit appears to be disrupted in most human tumors. A large number of 
additional TSGs have subsequently been identified, often associated with specific 
cancer forms2.  
 
Acquired mutations in proto-oncogenes and tumor suppressor genes provide a 
straightforward concept of how normal cells can obtain the physical characteristics 
associated with cancer cells. Clones of such cells are progressively capable of 
competing for space and nutrients within a species in a process highly analogous to 
Darwinian evolution. However, this model has turned out to be too simplistic, in 
part by the findings of epigenetically inactivated tumor suppressor genes but also 
by the high frequency of randomly distributed mutations seen in most malignant 
tumors27.  
 
2.3 Genomic maintenance genes 
 
Our genome is under constant attack by a variety of agents and processes that 
damage DNA. These mutagenic processes can be divided in three categories. First, 
the replication of DNA sequences prior to cell division is subject to a low, but 
significant level of intrinsic error. Second, the nucleotides within DNA undergo 
spontaneous chemical changes that often alter the base sequence and thus the 
information content of the DNA. Finally, DNA molecules are attacked by various 
mutagenic agents, including molecules generated by endogenous cellular 
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metabolism as well as those of exogenous origin, both chemical (e.g. tobacco tar 
and alkylating agents) and physical (e.g. X-rays and UV-light) mutagens. To 
counter these detrimental processes, an elaborate DNA repair system exists that 
constantly monitors the integrity of the genome. This system, associated with more 
than hundred different genes, is able to remove and replace inappropriate bases as 
well as repair strand breaks in DNA. In cases where the damage is too severe, the 
result is an induction of apoptosis in the damaged cell28.  
 
Defects in DNA repair genes lead to an increase in the overall mutation rate of the 
genome and inherited deficiencies in such genes predispose individuals to certain 
types of cancer29. Mice carrying mutated BRCA2* alleles show a high frequency of 
malignant thymic lymphomas and defects in DNA repair31. Moreover, a “mutator 
phenotype” acquired by cancer cells has been proposed to contribute to the 
morphologic and functional heterogeneity of human cancers and to be the reason 
why subpopulations of cells in a tumor can confer resistance to therapy27. Also, 
aberrant repair of DNA double-strand breaks is believed to be a major source of 
chromosomal translocations, attributing functions for DNA repair in keeping 
chromosomal structures intact32. These findings suggest that defects in DNA repair 
systems are causally linked to the development of many human cancers. 
 
Aneuploidy, abnormal chromosome numbers, is proposed to result from 
missegregation of chromosomes during mitosis. Mutations in a set of genes with 
functions in mitosis have been associated with cancer formation and such defects 
are believed to be responsible for the aneuploidy seen in many human cancer 
cells33.  
 
However, not all genetic changes contribute to cancer development and a 
distinction between primary causal aberrations and those accumulated as a 
consequence of tumor progression is in most cases difficult to reconcile. 
Fortunately, recent efforts have shown that such issues can be resolved by the use 
of high-throughput methods34.  
                                                 
* Women carrying mutated BRCA1 or BRCA2 genes have a high risk of developing breast and 
ovarian cancer [30]. 
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3. Fusion oncogenes 
 
Recurrent balanced rearrangements* have been found in almost every tumor type36 
and many of these changes are explicitly associated with distinct tumor phenotypes, 
clinical features and gene expression profiles. Recurrent balanced rearrangements 
are considered important early events during tumorigenesis and successful 
treatment of the associated disease is often paralleled by a decrease or loss of 
rearrangement-specific gene products. Furthermore, artificially constructed 
rearrangements in animal models give rise to tumors of the same kind as those 
sporadic human neoplasms that carry the corresponding rearrangements. In 
addition, experimental silencing of transcripts originating from recurrent 
rearrangements leads to a reversal of tumorigenicity, decreased proliferation and/or 
differentiation35. Recently, recurrent rearrangements were shown to occur in high 
frequencies in human prostate cancer37. These findings highlight the importance of 
such rearrangements for cancer progression and clinical outcome of many human 
cancers. 
 
Chromosomal translocations are the most commonly encountered balanced 
rearrangements and they exert their action through two alternative mechanisms. 
The first, deregulation of a gene through exchange of regulatory elements is well-
documented in hematological malignancies. In this type of translocation the 
promoter region of one gene is fused to the intact coding parts another gene by a 
process called promoter swapping (see Figure 1a). For example, in Burkitt 
lymphoma, which harbors one of three translocations, the MYC proto-oncogene is 
placed under the control of regulatory elements of an immunoglobulin gene and 
hereby becomes constitutively activated13,38. The second mechanism of fusion gene 
formation results in the creation of a chimeric fusion gene that comprises the 
coding regions of two different genes (see Figure 1b). The most famous example of 
a translocation creating a chimeric fusion gene came with the cloning of the 
Philadelphia chromosome† breakpoint. The Philadelphia chromosome was found to 
consist of material from both chromosomes 9 and 2241, and the later cloning of the 
breakpoint revealed a fusion between the 5’ part of BCR and the 3’ part of the 
ABL1 tyrosine kinase gene42,43. The rearrangement leads to the expression of a 
                                                 
* Chromosome abnormalities that result in structurally altered chromosomes without the gain or 
loss of genetic material. Reciprocal translocations, inversions and insertions comprise such 
changes [35]. 
 
† In 1960, Peter Nowell and David Hungerford reported that cells from patients diagnosed with 
chronic myeologenous leukemia (CML) had a normal number of chromosomes but that one 
chromosome was too small [39]. The findings were quickly confirmed by other cancer 
researchers and this marker became known as the Philadelphia chromosome, Ph. This was the 
first chromosome abnormality that was consistently associated with human malignancy [40]. 
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hybrid BCR-ABL1 protein with increased tyrosine kinase activity44. Treatment of 
CML patients with the ABL1-targeted receptor tyrosine kinase inhibitor imatinib 
induces complete remission in most cases45, demonstrating the central role of the 
BCR-ABL1 fusion in this disease.  
 
Figure 1. Mechanisms of fusion gene formation. a) Promoter swapping. b) Creation of chimeric 
genes. The figure illustrates reciprocal rearrangements between different chromosomes. Often 
only one functional gene product is expressed as a result of such rearrangements. Reciprocal 
translocations have to date not been linked to deficiencies in DNA repair systems. Adapted from 
Rowley 200140. 
 
3.1 FUS-DDIT3 
 
The FUS-DDIT3 fusion oncogene is formed by a t(12;16)(q13;p11) chromosome 
rearrangement46,47 that is highly specific for myxoid/round-cell liposarcomas 
(MLS/RCLS, see section 4) and detected in more than 90% of all cases*,53. The 
rearrangement results in the expression of an abnormal chimeric transcription 
factor54 (see Figure 2).  
                                                 
* Rare cases present clinically with the EWSR1-DDIT3 fusion oncogene [48]. To date there are 
nine FUS-DDIT3 and four EWS-DDIT3 variant fusion transcripts identified [49, 50]. However, 
the different transcript variants have not shown divergence in the ability to promote tumor 
development or affect the clinical outcome of MLS/RCLS [49, 51, 52]. 
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Figure 2. The t(12;16)(q13;p11) translocation, which results from a fusion of chromosomes 12 
and 16, leads to the expression of a chimeric fusion protein having the N-terminal FUS domain 
fused to the entire DDIT3 protein. The figure illustrates the most common fusion variant (type II) 
found in two thirds of all cases53. Characteristic sequence motifs such as Alu repetitive 
sequences, Translin55 binding sites and topoisomerase II cleavage sites have been found near the 
genomic breakpoints, which suggest that these regions are prone to somatic recombination and 
implicate Translin and topoisomerase II in the translocation process56-59. BR – basic region; G – 
glycine; LZ – leucine zipper domain; RGG – arginine, glycine, glycine repeats; RRM – RNA 
recognition motif; SYGQ – serine, tyrosine, glycine,  glutamine; TAD – transactivation domain; 
UTR – untranslated region; ZN – zinc finger motif. Regions were defined using 
UniProtKB/Swiss-Prot (http://www.uniprot.org/)60 and Ohaka 200761. Regions in DDIT3 are not 
drawn to scale. 
 
 
An aberrant transcription factor activity of FUS-DDIT3 has been demonstrated in 
vivo by studies showing distinct transcription profiles of tumor cells expressing the 
chimeric oncoprotein52,62,63. The FUS-DDIT3 protein is also implied in aberrant 
splicing and shown to inhibit YB-1-induced splicing in a dominant-negative 
manner64. We have previously identified a region in the N-terminal of FUS-DDIT3 
that is responsible for its temperature-dependent localization to splicing 
compartments defined by the SC-35 protein65, further implicating FUS-DDIT3 in 
abnormal RNA processing. 
 
Soon after its discovery, the FUS-DDIT3 gene was found to have transforming 
properties when expressed in cultured mouse fibroblasts66. It failed however to 
transform other cell types and was therefore suggested to elicit its oncogenic effects 
only in specific target cells. Further studies indicated that the N-terminal part of 
FUS was needed for realizing the full oncogenic potential of the chimera. 
Interestingly, when the FUS part was replaced with the N-terminal region of the 
highly homologous EWS protein this resulted in similar transforming properties. 
Conversely, the C-terminal was discovered to influence the tumor phenotype. 
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Tumors that emerged in nude mice upon injection with cells expressing fusion 
oncoproteins having different C-terminals showed distinct morphologies depending 
on the C-terminal transcription factor partner. From these experiments, it was 
concluded that the N-terminal is necessary for the transformation event while the 
C-terminal determines the specific tumor phenotype. These findings were later 
confirmed with FUS-DDIT3 transgenic mice67. In these mice, myxoid liposarcomas 
specifically developed in adipose tissues even though a ubiquitously activated 
promoter was used to drive FUS-DDIT3 expression in all tissues. Tumor formation 
required the co-expression of both FUS and DDIT3 domains but not necessarily in 
the form of a fusion protein68,69. A target cell population where FUS-DDIT3 could 
exert its transforming properties was subsequently identified using isolated mouse 
mesenchymal progenitor cells transduced with retroviral vectors carrying FUS-
DDIT362. These cells gave rise to myxoid liposarcomas resembling human 
counterparts when transplanted into SCID mice. Hence, FUS-DDIT3 was proposed 
to be the single causative factor of MLS/RCLS tumor formation in these mice. 
Concurrently, our group obtained evidence for an instructive role of the FUS-
DDIT3 protein, showing that FUS-DDIT3 expression induces a liposarcoma-like 
phenotype in tumors arising from primitive human fibrosarcoma cells implanted in 
SCID mice70. We and others have also demonstrated that FUS-DDIT3 can block 
adipogenesis70-73, the process whereby a mesenchymal stem cell matures into a 
post-mitotic, fat-laden adipocyte74. Thus, the ability of FUS-DDIT3 to transform 
pluripotent mesenchymal progenitor cells, FUS-DDIT3 transgenic mice showing 
adipose tumors, and the induced liposarcoma-like phenotype seen in xenografts, 
support a model wherein FUS-DDIT3 transforms a mesenchymal stem cell and 
further commits it to the adipocytic lineage with subsequent blockage of terminal 
differentiation.  
 
The transformation event caused by FUS-DDIT3 is poorly characterized at the 
molecular level while the blockage of differentiation is mapped in more detail. The 
normal DDIT3 protein is known to form heterodimers with C/EBP members*,76 and 
this ability is retained by the oncogenic FUS-DDIT3 protein77. C/EBP proteins play 
a prominent rule in adipogenesis during which these transcription factors are 
expressed in a cascade. Induction of C/EBPβ and C/EBPδ occurs in the first stages 
of adipogenesis and further trigger the expression of C/EBPα and PPARγ, the 
master regulator of fat differentiation. A positive feedback loop between C/EBPα 
and PPARγ leads to the expression of mature adipocyte markers such as ap2, 
adiponectin and adipsin. FUS-DDIT3 is able to block terminal differentiation of 
                                                 
* The CCAAT-enhancer-binding protein family of transcription factors consists of six members 
that are involved numerous cellular processes including differentiation, proliferation, 
inflammation/immune response, apoptosis and control of metabolism. The members share 
substantial sequence similarity in the C-terminal that contains a DNA-binding region enriched in 
basic amino acids followed by a leucine zipper dimerization domain [75]. 
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preadipocytes by sequestration of C/EBPβ which inhibits transcriptional activation 
of CEBPA and PPARG. In addition, FUS-DDIT3 is proposed to upregulate early 
translation factors eIF4E and eIF2 through promoter activation, which could alter 
the distribution of C/EBP isoforms and invoke a negative effect on adipogenesis73. 
 
3.2 DDIT3 
 
The DDIT3 (CHOP, GADD153) gene was first identified as being transcriptionally 
induced in response to growth arrest and DNA damage78, and later in response to 
glucose deprivation, inflammation, oxidative and endoplasmatic reticulum (ER) 
stress79-82. It is mapped to human chromosome 12 (12q13.1-q13.2) and consists of 4 
exons83. The encoded DDIT3 protein (see Figure 2) belongs to the C/EBP family75 
of transcription factors and forms heterodimers with the other family members. 
DDIT3 differs from other C/EBP proteins in that it contains two proline residues in 
the DNA-binding basic region that disrupts its α-helical structure, while retaining 
an intact leucine zipper needed for dimerization. As a result, DDIT3 heterodimers 
are unable to bind canonical C/EBP recognition sites and consequently act as 
dominant-negative regulators of transcription by sequestering C/EBP members76. 
However, DDIT3-C/EBP heterodimers have been shown to activate gene 
transcription under certain conditions by binding alternative DNA sequences84. 
Moreover, DDIT3 is able to regulate transcription by forming dimers with other 
transcription factor families containing basic-leucine zipper regions85,86. DDIT3 
was recently identified as an intrinsically disordered protein able to form 
homooligomers through its N-terminal region87. This oligomerization state was 
further suggested to be central for both inhibition of Wnt/Tcf signaling88 and 
activation of c-Jun and sucrase-isomaltase promoters87. The transactivating ability 
of DDIT3 is enhanced in response to stress89 and the protein inhibits adipogenesis 
in response to metabolic stress90. DDIT3 was also shown to induce growth arrest at 
the G1/S transition, which required an intact basic region as well as the leucine 
zipper domain77. Finally, the protein mediates apoptosis induced by ER stress91,92 
and is therefore implicated in diseases with ER stress-dependent cell death, such as 
neurodegenerative disorders and diabetes93,94.  
 
3.3 FUS, EWS and TAF15 
 
FUS (TLS), EWS and TAF15 (RBP56, TAF2N) are three structurally similar 
proteins that belong to the FET family (previously TET family) of RNA-binding 
proteins. The proteins share a number of highly conserved regions including an N-
terminal serine-tyrosine-glycine-glutamine (SYGQ) rich region, a central RNA-
recognition motif (RRM), a cysteine2/cysteine2-zinc finger and numerous C-
terminal arginine-glycine-glycine (RGG) repeats (see Figure 3). The FET proteins 
are shown to bind DNA, RNA and protein by these unique structural features95. 
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FUS, EWS and TAF15 are involved in a wide range of cellular processes. The 
proteins bind both eukaryotic RNA polymerase II and transcription factor II D 
(TFIID) complex proteins and are thus implicated in early transcriptional events95-
99. In addition, the FET proteins are involved in RNA splicing64,99,100-107 and may 
furthermore function in primary microRNA* processing as they have been shown to 
associate with the large Drosha microprocessor complex109. The FET proteins 
shuttle between different cellular compartments in complexes consisting of 
heterogeneous nuclear ribonucleoproteins (hnRNPs) and mRNA, which implicates 
these proteins in RNA transport66,110-116. Moreover, the FET proteins are reported 
targets for tyrosine kinase phosphorylation113,117-120 and implied in additional 
signaling pathways121. Bertrand et al. previously reported cell cycle-dependent 
homologous DNA pairing activity for FUS122 and such activity was subsequently 
also reported for EWS and TAF15123. FUS and EWS knockout mice are sensitive to 
ionizing radiation and show defects in meiosis and B-lymphocyte development. 
The FUS and EWS genes were additionally required for genomic stability in these 
mice124-126. Recently, FUS was shown to be a target for ATM phosphorylation 
following experimentally induced DNA double-strand breaks127. Furthermore, FUS 
was demonstrated to inhibit transcription of the CCND1 gene by interfering with 
p300 acetyltransferase activity. This inhibitory effect was induced by ionizing 
radiation and further mediated by the elevated expression of noncoding RNAs 
(ncRNAs) expressed from the CCND1 promoter. Remarkably, these ncRNAs 
recruited and allosterically modified FUS, which lead to a transcriptional inhibition 
acting in cis on the CCND1 gene. Similarily, EWS and TAF15 showed inhibitory 
effects on p300 acetyltransferase activity in these experiments. These findings 
demonstrated a novel ncRNA/RNA-binding protein-based mechanism of 
                                                 
* MicroRNAs are small, non-coding RNAs with regulatory functions. These may play an 
important role in many human diseases, including cancer, and several studies have shown that 
these RNA species can act as both oncogenes and tumor suppressor genes [108]. 
Figure 3. Schematic comparison of FET family proteins. 
Numbers indicate amino acids. Each protein also has one 
shorter isoform (not shown). Regions were defined using 
UniProtKB/Swiss-Prot. Regions are drawn to scale. 
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transcriptional regulation128. Collectively, these results attribute roles for the FET 
proteins in maintaining genomic integrity by acting as mediators of DNA repair 
through transcriptional regulation and homologous DNA pairing and 
recombination.  
 
The FUS, EWSR1 and TAF15 genes reside on chromosomes 16, 22 and 17 
respectively, and are ubiquitously expressed in human adult and fetal tissues129-132. 
Though, how their expression is regulated remains poorly understood. The 5’ 
flanking sequences contain multiple transcription start sites, lacks TATA boxes and 
has a high incidence of C and G nucleotides, features associated with promoter 
regions of many housekeeping genes129,131,132. The FET genes are rearranged in 
numerous tumor type-specific chromosomal translocations found in human 
malignancies36 (see Figure 4). The resulting fusion genes consist of parts of FET 
genes in 5’ and different transcription factor coding genes in their 3’. 
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Figure 4. Fusion oncogenes involving FET family members. Nodes depict genes while 
connectors show associated tumor diseases. AFH - angiomatoid fibrous histiocytoma; ALL – 
acute lymphocytic leukemia; AML – acute myeloid leukemia; AUL – acute undifferentiated 
leukemia; CCS – clear cell sarcoma; DSRCT – desmoplastic small round cell tumor; EMC – 
extraskeletal myxoid chondrosarcoma; EFT – Ewing family of tumors including Ewing sarcoma 
and primitive neuroectodermal tumors; FMS – fibromyxoid sarcoma; HA – hidradenoma of the 
skin; MEC – mucoepidermoid carcinoma of the salivary glands; MLS – myxoid/round-cell 
liposarcoma; STT – soft tissue tumor, special type. The network is based on data contained in the 
Mitelman Database of Chromosome Aberrations in Cancer36. 
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4. Myxoid liposarcoma 
 
Myxoid liposarcoma is the second most common subtype of liposarcoma and 
constitutes about 10% of all adult soft tissue sarcomas. The tumors occur 
predominantly in the deep soft tissues of the extremities and arise in more than two-
thirds of cases in the musculature of the thigh. MLS has a peak incidence between 
40 and 60 years of age with no gender predilection. It is prone to recur locally and 
one-third of the patients develop distant metastases. MLS tends to metastasize to 
unusual soft tissue sites (i.e. retroperitoneum, opposite extremity, axilla) or bone 
(preferentially to spine) before spreading to lung. In a significant number of cases, 
patients present clinically with synchronous or metachronous multifocal disease53. 
 
MLS tumors are composed of uniform round to oval shaped primitive nonlipogenic 
mesenchymal cells and a variable number of small signet-ring lipoblasts, contained 
in a prominent myxoid stroma with a rich branching vascular pattern. A subset of 
these tumors shows histological progression to hypercellular or round-cell 
morphology characterized by closely packed primitive round cells with no 
intervening myxoid stroma, a high nuclear to cytoplasmic ratio and clearly visible 
nucleoli. The presence of areas with gradual transition from myxoid to round-cell 
morphology in some tumors provides evidence that RC liposarcoma represents a 
histological continuum of MLS53. 
 
Fine needle aspiration is routinely used for morphologic diagnosis and the further 
presence of FUS-DDIT3 or EWSR1-DDIT3 transcripts, expressed as a result of 
cytogenetically detectable translocations, is a specific indicator of myxoid 
liposarcoma53. Other cytogenetic abnormalities are rarely seen in these tumors. 
High histological grade (≥ 5% RC component), presence of necrosis and p53 
overexpression are associated with a significantly poorer prognosis51.  
 
The main treatment regime is surgery which is combined with chemotherapy 
(ifosfamide, doxorubicin) for advanced or unresectable disease133. Several studies 
have shown that preoperative radiation therapy results in improved local control 
and significant tumor volume reduction134-137. Conflicting clinical responses were 
obtained in two studies using PPARγ agonists for treatment of MLS/RCLS138,139. 
Recently, antitumor activity of the DNA minor groove-binding alkaloid trabectedin 
was shown in patients with advanced MLS/RCLS140. The 5-year survival of 
myxoid liposarcoma is approximately 70% while the 10-year survival of patients 
that present with a localized disease showing >5% RC component decline to 30%51. 
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Aims of the thesis 
 
The objectives of this thesis were to analyze the expression of the FET family 
proteins (FUS, EWS, TAF15) in cells of normal tissues and to clarify the molecular 
mechanisms behind FUS-DDIT3-induced tumorigenesis. 
 
The overall aim of our cancer research group is to search for shared mechanisms of 
transformation in tumors carrying FUS, EWS and TAF15 fusion oncogenes. 
 
The global goal of cancer research is to define the molecular defects giving rise to 
cancer and to turn these discoveries into effective treatment and prevention 
regimens. 
 
 
The main aims of the papers included in this thesis were the following: 
 
Paper I – To characterize the expression patterns of FUS, EWS and TAF15 in 
human tissues and cells. 
 
Paper II – To elucidate the molecular mechanisms behind opposing IL8 
transcription in FUS-DDIT3 and DDIT3 expressing cells. 
 
Paper III – To investigate the significance of the putative FUS-DDIT3 target gene 
FLT1 in myxoid liposarcoma etiology. 
 
Paper IV – To study the role of FUS-DDIT3 in the abnormal expression of cell 
cycle regulators seen in myxoid liposarcomas. 
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Materials and methods 
 
Formalin-fixed paraffin-embedded tumor tissue from seven cases diagnosed with 
myxoid/round-cell liposarcoma was used for immunohistochemical analysis. In 
addition, MLS/RCLS tumor tissue from SCID mice xenografts, human normal 
organ and various cancers tissue arrays (Super Bio Chips) and angiosarcoma tissue 
were analyzed by immunohistochemistry. Total RNA was extracted from three 
fresh-frozen MLS/RCLS tumors as well as from adipose tissue and isolated 
adipocytes of healthy individuals, and used for quantitative real-time PCR. The 
MLS/RCLS-derived cell lines 402-91, 1765-92 and 2645-9463,141 as well as HT-
1080 human fibrosarcoma cells142 and stably transfected subclones of this cell line70 
were used in molecular studies. In addition, HeLa cells, SH-SY5Y neuroblastoma 
cells143, U1242MG glioblastoma cells144, F470 primary human fibroblasts145 and 
human embryonic stem cell lines SA121 (Cellartis AB), HUES1146 and HUES3146 
were used for quantitative real-time PCR and immunofluorescence studies.  
 
The results presented in this thesis are based on multiple molecular and cell 
biological methods such as: human cell culture, experimental cell assays, 
recombinant DNA techniques, stable and transient transfections, RNA interference, 
colocalization studies, luciferase reporter assays, chromatin- and co-
immunoprecipitations, immunohistochemistry/immunofluorescence, fluorescence 
microscopy, laser scanning confocal microscopy, western blot analysis, quantitative 
real-time PCR, microarray analysis and liquid chromatography-mass spectrometry.  
 
Statistical tests included independent samples t-test and Spearman correlations. 
 
See the individual papers (I-IV) for detailed descriptions of the materials and 
methods used. 
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Results and discussion 
 
Paper I. Cell type-specific expression of FET family proteins 
 
Organ homeostasis in the multicellular organism is governed by temporal 
expression of tissue-specific transcription factors147 and deregulation of this timely 
expression can lead to cancer development through perturbation of normal 
differentiation programmes5.  
 
The presence of translocated FET genes in tumors arising in a wide range of organs 
and the consistent association of these genes with tumor type-specific transcription 
factor coding fusion partners (see Figure 4), prompted us to characterize normal 
FET protein expression in human tissues and cells. In this work, we performed 
immunohistochemical analyses of human tissue microarrays with FET-targeted 
antibodies.  
 
Our results showed that the three proteins are ubiquitously expressed throughout 
human tissues and only a few cell types lack FET expression. The FET proteins 
were expressed in the nuclei of all positive cells and FUS and TAF15 were 
expressed in the cytoplasm of most cells types. EWS was normally restricted to the 
nucleus and the few cell types wherein EWS showed cytoplasmic expression were 
generally secretory cell types, suggesting functions for EWS in the expression of 
secreted proteins. In addition, individual cells in tissues showed variations in FET 
expression levels, even within the same cell type. Such divergence was absent in 
cultured cells, which showed similar expression levels of the three proteins. This 
could indicate roles for the FET proteins in regulation of specialized functions. The 
nature of these cell type-specific functions is yet to be clarified but they are likely 
connected with regulation of cell type-specific transcription147 and splicing148 
during tissue development and homeostasis. Roles for the FET proteins at different 
stages of maturation is further supported by our findings of downregulated FET 
protein expression in neuroblastoma cells experimentally induced to differentiate, 
the attenuated FET gene expression seen in spontaneously differentiating human 
embryonic stem cells and the absence of FET expression in some terminally 
differentiated cell types. Previous studies have also shown alterations in FUS and 
EWS expression during maturation of specific cell types118,149-151. In terms of 
mechanisms for FET protein regulation, one study reported that FUS expression is 
in part controlled by proteaosome-mediated degradation regulated by PKCβII-
dependent phosphorylation, c-Jun expression and possibly hnRNPA1 
ubiquitination152. The stability of the EWS protein has been linked with arginine 
methylation in its C-terminal region153.  
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In cultured cells, the three FET proteins localized to stress granules* upon heat and 
oxidative stress. The FET proteins therefore appear to be part of the normal cellular 
response to stress. Perturbation of cellular stress responses in cancer cells leads to 
avoidance of growth inhibition and thereby maintained proliferation of damaged 
cells. Moreover, FUS and TAF15 localized to early spreading initiation centers, 
structures that contain RNA and RNA-binding proteins, involved in cell spreading 
and adhesion. Disturbance of such processes could promote characteristics 
associated with invasion and metastasis. 
 
In conclusion, this work suggests cell type-specific activities for the FET family 
proteins and involvement in stress response and cell spreading. Proteins with 
multiple functions are vulnerable targets for cancer-causing mutations as such 
mutations could induce a simultaneous deregulation of multiple cellular control 
systems. This may explain why few additional genetic abnormalities are detected in 
tumors expressing FET fusion oncogenes. Furthermore, fusion of FET genes to 
transcription factor coding genes leads to an unscheduled expression of aberrant 
oncogenic transcription factors governed by FET family expression. As expression 
of the FET family is attenuated upon differentiation, this work suggests that agents 
which are able to induce differentiation of cells may reduce expression of chimeric 
FET oncoproteins.  
 
 
                                                 
* Stress granules are dense cytoplasmic aggregates that are composed of stalled translation pre-
initiation complexes, mRNAs, microRNAs and RNA-binding proteins. These particles appear in 
cells exposed to a range of cellular stresses [154]. 
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Paper II. Mechanisms of IL8 regulation by FUS-DDIT3 
 
Transcription factors are proteins that bind specific regulatory DNA sequences of 
target genes and hereby control the transfer (i.e. transcription) of genetic 
information from DNA to RNA155. A transcription factor can perform this function 
alone or in complex with other proteins and the result is either an activation or 
repression of gene transcription.  
 
We have previously reported differential regulation of interleukin 8 (IL8) 
transcription in cells stably expressing DDIT3 and FUS-DDIT3 proteins156. In these 
cells, the DDIT3 protein seemingly acts as a strong repressor of IL8 expression, 
while FUS-DDIT3 instead activates expression of IL8. In the present work, we 
investigate the molecular mechanism behind this opposing effect on IL8 activity.  
 
The IL8 promoter contains a C/EBP–NF-κB composite site and the gene is 
reportedly regulated by C/EBP and nuclear factor kappa B* (NF-κB) transcription 
factors158. We explored the functional relevance of this site for IL8 expression in 
our system by using plasmid vectors carrying mutant IL8 promoters in frame with 
the coding regions of firefly luciferase. These reporter constructs were transfected 
into cells having stable DDIT3 or FUS-DDIT3 expression and the transcriptional 
activity of the different promoters was estimated by measurements of the luciferase 
enzymatic activity. In control cells (expressing neither DDIT3 nor FUS-DDIT3), 
the C/EBP site was judged to be important for IL8 transcriptional regulation as 
mutation of this region resulted in a strong reduction of the IL8 transcriptional 
activity. In contrast, the NF-κB part of the composite site was involved in negative 
regulation of IL8 as mutation here lead to an increased transcription. Stable and 
transient expression of DDIT3 caused downregulation of IL8 mRNA and 
ectopically expressed DDIT3 lacking the leucine zipper domain retained the ability 
to suppress IL8 expression. These findings suggest that DDIT3 exerts its inhibitory 
action on IL8 independently of C/EBP proteins. A recent study showed that DDIT3 
lacking the C-terminal region can indeed regulate IL8 transcription by binding an 
upstream responsive element in the IL8 promoter159. However, the results obtained 
from our model indicate that the inhibitory effect seen by DDIT3 on the IL8 
promoter is mediated by a factor binding to the NF-κB promoter site, as mutation 
of this region strongly counteracted the repressing effects imposed by DDIT3 on 
IL8. Expression of FUS-DDIT3 on the other hand caused an increased IL8 
transcription that was maintained in the absence of the C/EBP site. The prominent 
IL8 expression was instead dependent on the NF-κB site and mutation of this site 
led to a dramatic reduction of IL8 transcription in FUS-DDIT3 expressing cells. 
Chromatin immunoprecipitation assays further confirmed that FUS-DDIT3 
                                                 
* The NF-κB system is composed of the NF-κB/Rel and IκB families and involved in immunity, 
oncogenesis and development [157]. 
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associates with the IL8 promoter in myxoid liposarcoma cells. Moreover, FUS-
DDIT3 expressing cells were resistant to the dominant-negative effects induced by 
DDIT3 on IL8 transcription. These results imply a tight association between FUS-
DDIT3 and the IL8 promoter. However, the analyses could not reveal whether this 
association was through a direct binding of the IL8 promoter or mediated by an NF-
κB site binding protein. As FUS-DDIT3 has not been reported to bind NF-κB sites 
of gene promoters, we hypothesized that FUS-DDIT3 might interact with an NF-κB 
family member and hereby induce IL8 expression. We performed systematic 
colocalization studies between FUS-DDIT3 and NF-κB family members and 
identified NFKBIZ as a putative nuclear interaction partner of FUS-DDIT3. By 
transient transfections, we demonstrated that ectopically expressed FUS-DDIT3 
colocalizes with NFKBIZ in nuclear speckles. Furthermore, FUS-DDIT3 was able 
to translocate a cytoplasmically localized NFKBIZ mutant to the nucleus.  
Truncated forms of FUS-DDIT3 showed reduced ability to associate with NFKBIZ, 
which could explain the opposing effects seen between FUS-DDIT3 and DDIT3 on 
IL8 expression. The interaction between FUS-DDIT3 and NFKBIZ was confirmed 
by co-immunoprecipitation experiments in which we could show that FUS-DDIT3 
binds the C-terminal of NFKBIZ. Our results imply that FUS-DDIT3 and NFKBIZ 
bind directly or are present in a common complex and hereby regulate IL8 
transcription. To further strengthen this hypothesis, we showed that ectopically 
expressed NFKBIZ was on its own able to induce expression of IL8, IL6 and LCN2 
in our experimental system, genes which are highly transcribed in FUS-DDIT3 
expressing cell lines.  
  
Based on these results, we here propose a novel mechanism of FUS-DDIT3-
mediated gene regulation in which the fusion oncoprotein augments expression of 
NF-κB target genes through a cooperative action with the NF-κB protein NFKBIZ. 
This model is further supported by our previous findings of FUS-DDIT3-driven 
expression of the NF-κB-controlled IL6 gene156. Elevated serum levels of IL6 and 
IL8 are demonstrated as independent prognostic factors of soft tissue sarcomas and 
associated with a significantly shortened overall survival of patients160. These 
factors participate in inflammation-related carcinogenesis through stimulation of 
cell proliferation, angiogenesis, invasion, metastasis and inhibition of 
apoptosis161,162. Thus, the functional interaction between FUS-DDIT3 and the NF-
κB system, which plays a central role during inflammation163, suggests a role for 
inflammation-related processes during myxoid liposarcoma tumorigenesis.  
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Paper III. FLT1 and PGF expression in FUS-DDIT3 carrying cells 
 
Normal cells receive stimulatory signals from their surroundings that are processed 
and integrated into a complex network of pathways within the cell. This signaling 
subsequently leads to a decision of whether the cell should divide or remain 
quiescent. Such regulation is essential to preserve cellular homeostasis in tissues of 
multicellular organisms. Many stimulatory signals are conveyed by growth factors* 
released by certain cells and these factors bind to growth factor receptors on the 
surface other cells. Deregulation of growth factor and growth factor receptor 
expression is associated with multiple forms of human cancer164. 
 
In this paper, we have studied the expression of the growth factor receptor FLT1 
(VEGFR1) in FUS-DDIT3 carrying cells. FLT1 belongs to the VEGFR family of 
receptor tyrosine kinases and is a receptor for PGF, VEGFA and VEGFB. Its best 
known role is in regulation of angiogenesis but it has also been associated with 
tumor growth and invasiveness of cancer cells165. Previously collected microarray 
data indicated that FLT1 is upregulated in FUS-DDIT3 expressing cells70. We 
investigated this finding further by quantitative real-time PCR analysis of HT1080 
human fibrosarcoma cells stably expressing FUS-DDIT3, DDIT3 or the N-terminal 
of FUS present in the type II fusion. Cells expressing ectopic FUS-DDIT3 showed 
more than 20 times higher FLT1 expression than untransfected HT1080 cells and 
DDIT3 expressing cells also showed minor but significant upregulation of FLT1 
expression. In contrast, cells expressing the 5’ part of the FUS gene showed a slight 
downregulation of FLT1 mRNA. Three cell lines derived from MLS/RCLS 
expressed high levels of FLT1 transcripts, which further demonstrated that FLT1 is 
expressed in FUS-DDIT3 carrying cells. However, when HT1080 cells were 
transiently transfected with plasmid vectors expressing the above proteins, no 
changes in FLT1 expression were detected during a 48 hour observation period. 
Therefore, the upregulated FLT1 expression seen in cell lines with stable FUS-
DDIT3 expression may not be directly attributed to a transcriptional activation by 
FUS-DDIT3. The FUS-DDIT3 protein has the capacity to induce adipocytic 
characteristics in HT1080 cells and the upregulation of FLT1 expression could 
hence be a part of this process. This hypothesis is supported by measurements 
showing high FLT1 expression in isolated normal adipocytes. 
 
Immunohistochemical analysis of tumor tissue from patients diagnosed with 
myxoid liposarcoma and an MLS cell line xenografted in SCID mice showed a 
strong, predominantly nuclear expression of the FLT1 protein in tumor cells. 
Similar results were obtained from immunofluorescence analysis of cultured MLS-
derived cells. The nuclear localization was surprising since FLT1 is commonly 
                                                 
* Relatively small soluble proteins capable of stimulating growth, proliferation and 
differentiation. 
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reported in the plasma membrane or cytoplasm166. Thus, we prepared nuclear and 
cytoplasmic fractions from the MLS/RCLS-derived cell line MLS 402-91 and 
analyzed these by western blot using an FLT1 specific antibody. This analysis 
confirmed the nuclear expression of the protein seen with immunostaining. We 
further analyzed whether FLT1 shows a nuclear localization in other tumor types 
and normal tissues. For this purpose, we used immunohistochemical analysis of 
human tissue arrays containing 59 normal and 60 tumor-derived tissues. In tumors, 
we observed strong nuclear staining of FLT1 in pancreatic carcinoma and ovary 
carcinoma. Mesenchymal cells present in several normal tissues also showed 
nuclear localization of FLT1 and most notably FLT1 antibodies stained the nuclei 
of adipocytes, suggesting that nuclear FLT1 is a normal feature of this cell type. In 
addition, fibroblasts in culture showed prominent FLT1 staining in the nucleus but 
had a stronger cytoplasmic staining compared with cultured MLS cells. These 
observations imply functions for FLT1 in the nuclear compartment of these cells 
and such functions have been reported for other receptor tyrosine kinases167,168. 
 
Microarray data from FUS-DDIT3 expressing HT1080 cells further suggested that 
PGF, encoding placental growth factor (PGF), could be transcribed in MLS cells. 
PGF expression is increased in several human cancers and serum levels of the 
encoded PGF correlate with clinicopathological features of multiple human 
malignancies165. Hence, we analyzed the expression of PGF in cultured MLS cells 
and MLS tumor tissue by quantitative real-time PCR. Results showed that PGF 
was indeed expressed in cultured MLS cells and to a much higher degree than in 
normal adipocytes. We also detected PGF expression in cultured MLS 402-91 cells 
by immunofluorescence. In contrast, VEGFA and VEGFB, encoding the other 
ligands of FLT1, were expressed to considerably lower levels in MLS cells than in 
adipocytes. These results suggest the existence of an autocrine circuit involving 
PGF and FLT1 operating in cultured MLS cells. However, analysis of MLS tumor 
tissue showed a more heterogeneous expression of the ligand coding genes, which 
could result from differences of in vitro and in vivo ligand expressions. 
  
We assayed the presence of an autocrine loop in MLS cells by incubating the cells 
with an FLT1 blocking antibody reported to inhibit growth of tumor cells 
dependent on FLT1 signaling169. Treatment with this antibody failed however to 
affect the growth of MLS cells. The nuclear localization of FLT1 seen in MLS cells 
could be the reason for this as receptor-targeted antibodies would be ineffective if 
the receptor and ligand interact inside the plasma membrane. Such intracrine 
growth stimulatory circuits involving FLT1 were recently reported in mammary 
carcinoma cells170. To test for the presence of an intracrine circuit in MLS cells, we 
performed knockdown experiments using short interfering RNAs (siRNAs) 
targeting FLT1 and PGF mRNA. However, we were not able to achieve efficient 
knockdown of transcripts in these cells and could not determine the existence and 
importance of such an intracrine signaling loop in MLS. 
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We conclude that the upregulation of FLT1 seen in MLS is an indirect downstream 
effect of FUS-DDIT3 expression, which can induce a liposarcoma-like phenotype. 
The FLT1 protein is expressed as a nuclear protein in MLS tumors, in additional 
nonmesenchymal tumors as well as in normal mesenchymal cell types. This implies 
functions for FLT1 in the nuclear compartment of certain cells. The expression of 
the FLT1 ligand gene PGF in MLS cells suggests the existence of auto- or 
intracrine loops operating in these cells and such circuits could be of therapeutic 
relevance in treatment of myxoid liposarcomas. 
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Paper IV. DDIT3 binding of cyclin-dependent kinase 2 
 
The cellular decision to divide or remain quiescent is ultimately governed by the 
cell cycle. This signal processing unit receives stimuli of both extracellular and 
intracellular origin and integrates these into a complex molecular control circuitry. 
Roughly, the cell cycle is divided into four phases* that comprise sequential 
phosphorylations of the pRb tumor suppressor protein by different cyclin/cyclin-
dependent kinase (CDK) complexes. Completion of the entire cell cycle leads to 
DNA replication and cell division171. 
 
We have previously reported that MLS/RCLS cells show abnormal expression of 
the cell cycle regulators cyclin D and E as well as their associated cyclin-dependent 
kinases CDK4 and CDK2172. In this work, we searched for putative interaction 
partners of FUS-DDIT3 among G1 cyclins and CDKs, as these might provide 
insights into the molecular mechanisms by which the chimeric oncoprotein induces 
malignancy. 
 
By transiently transfecting HT1080 cells with a FUS-DDIT-GFP construct, we 
could show that, in cells expressing the encoded recombinant protein, endogenous 
expression patterns of cyclin E and CDK2 were altered and that these proteins 
showed overlap with FUS-DDIT3 in the nuclear speckles previously reported for 
the fusion oncoprotein145. We thus speculate that translocation of cyclin/CDK 
complexes to such foci may result in changed phosphorylation patterns and 
substrate specificity for these complexes. To further confirm and interaction 
between FUS-DDIT3 and cyclin E/CDK2, we performed co-immunoprecipitation 
experiments using ectopically expressed variants of the fusion protein tagged with 
GFP. The experiments demonstrated that the DDIT3 part of the fusion binds to 
CDK2, while cyclin E was not found in immunoprecipitates. These results 
displayed similarities with previous reports showing that the DDIT3-related 
C/EBPα can disrupt cyclin/CDK complexes and thereby inhibit their activity173. 
However, we can not rule out that the absence of cyclin E in immunoprecipitates 
was due to the low levels of endogenous cyclin E detected in the cells used for 
these experiments. Further studies, using a mutant FUS-DDIT3 construct lacking 
the sequences encoding the leucine zipper motif, showed that this domain was 
redundant for CDK2 binding. This suggests that DDIT3 binds CDK2 independently 
of heterodimerization with other C/EBP family members. When we performed 
                                                 
* During the S phase a cell synthesizes a replica of its genetic material DNA. In the M phase a 
cell undergoes mitosis and partitions all cellular components into two daughter cells. These 
phases are separated by the two tightly regulated “gap” phases G1 and G2, where the cell 
prepares for successful completion of the S and M phases. Cells that have ceased to proliferate, 
either by receiving anti-mitogenic signals, or by the lack of sufficient mitogenic stimuli, enter a 
nondividing, quiescent state termed G0. 
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sequence alignments between C/EBPα (which contains a region shown to bind and 
inhibit CDK2173) and DDIT3, we were unable to find a similar region in the DDIT3 
protein, which implies that DDIT3 binds CDK2 in a different manner than C/EBPα. 
 
In order to examine the biochemical relevance of a binding between DDIT3/FUS-
DDIT3 and CDK2, we analyzed expression levels, half-life and the status of 
activating or inhibiting phosphorylations of CDK2 proteins present in FUS-DDIT3 
expressing cells. Though, we did not detect significant differences in these 
parameters between FUS-DDIT3 expressing cells and control cells. To further 
analyze the functional effects of the DDIT3/FUS-DDIT3 and CDK2 interaction, we 
immunoprecipitated CDK2 from cells transfected with DDIT3, FUS-DDIT3 and 
GFP constructs. Mass spectrometric analysis of the precipitates obtained from these 
experiments revealed an enhanced binding of CDK2 to components of the 
cytoskeleton in DDIT3 and FUS-DDIT3 expressing cells. Such an alteration in 
binding affinity could result in a change of the overall cytoskeleton structure, 
possibly leading to deregulation of motility.  
 
To summarize, we demonstrate that endogenous CDK2 is translocated to nuclear 
structures characteristic for FUS-DDIT3 and that it binds to the DDIT3 part of the 
fusion oncoprotein. Cyclin E is also recruited to such nuclear structures but can not 
be found in DDIT3/FUS-DDIT3 immunoprecipitates. The interaction between 
DDIT3 and CDK2 appears to alter the protein binding affinity of CDK2, possibly 
leading to changed phosphorylation patterns and deregulation of cytoskeletal 
proteins in DDIT3 and FUS-DDIT3 expressing cells. In contrast to FUS-DDIT3, 
DDIT3 has been found to induce growth arrest as well as block adipogenesis under 
certain conditions77,90 and phosphorylation of the DDIT3-binding C/EBPβ by 
CDK2 is required for adipogenesis174. In light of these findings, our results suggest 
that inhibition of proliferation and differentiation by DDIT3 could be mediated 
through an interaction with CDK2. Deregulation of proliferation, differentiation 
and cell motility are traits associated with the cancer phenotype. Hence, the 
significance of binding between FUS-DDIT3 and CDK2 in the context of myxoid 
liposarcoma development remains to be investigated. 
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Conclusions 
 
The main findings of this thesis are concluded as follows: 
 
• The FET proteins show heterogeneous cell type-specific expression patterns 
in human tissues and cells. Their expression levels are altered upon 
differentiation and they localize to stress granules in response to cellular 
stress. Furthermore, FUS and TAF15 localize to spreading initiation centers 
upon early cell spreading. Our results point to cell type-specific functions for 
the FET family proteins in regulation of gene expression during both normal 
and stress conditions (Paper I). 
 
• FUS-DDIT3 deregulates expression of the NF-κB target gene IL8 through a 
cooperative action with the NF-κB protein NFKBIZ. Together with previous 
findings of elevated IL6 expression in MLS/RCLS cells, these results suggest 
a mechanism of FUS-DDIT3-driven tumorigenesis through deregulation of 
of NF-κB target genes. Our results further propose a role for inflammation-
related processes in MLS/RCLS development (Paper II).  
 
• The upregulation of FLT1 seen in FUS-DDIT3 expressing cells is likely a 
downstream result of a FUS-DDIT3-induced liposarcoma-like phenotype. 
Nevertheless, the nuclear expression of FLT1 and the expression of its ligand 
PGF in myxoid liposarcoma cells suggest the existence of an intracrine 
signaling loop in these cells (Paper III). 
 
• FUS-DDIT3 binds the cell cycle regulator CDK2 through its DDIT3 part and 
this interaction alters the binding specificity of CDK2 to an increased affinity 
for cytoskeletal proteins. Our results imply that the inhibition of proliferation 
and differentiation caused by DDIT3 could be mediated by an interaction 
with CDK2. However, the significance of a binding between FUS-DDIT3 
and CDK2 in the context of myxoid liposarcoma development remains to be 
clarified (Paper IV). 
 
The multifunctionality of the normal FET proteins may explain why their 
oncogenic counterparts are often the sole detectable abnormalities in their 
associated tumors. Specifically, the FUS-DDIT3 protein studied in this thesis may 
promote several of the physical characteristics known as the hallmarks of cancer 
and thereby drive malignancy. Obviously, a direct targeting of FUS-DDIT3 would 
be optimal in the clinical setting. However, this work suggests that agents which 
induce cellular differentiation, inhibit inflammatory processes (in particular the NF-
κB system) or block FLT1/PGF signaling may aid current treatments and thereby 
improve survival of patients afflicted with myxoid liposarcoma. 
FET proteins in cancer and development 
 
Future perspectives 
 
35 
Future perspectives 
 
With the advent of next generation DNA sequencing, whole-genome sequencing is 
now possible at a reasonable cost and timeframe175. We are now able to identify 
genetic changes at single base level in cytogenetically normal cells. Recently, such 
methods were successfully applied to analyze cells obtained from a patient 
suffering from acute myeloid leukemia, identifying eight previously unknown 
mutations believed to contribute to the progression of this disease176. These new 
techniques can hopefully soon be used to discover cancer-promoting mutations also 
in genomically unstable cells. The next big challenge will be to functionally 
characterize such mutations in an effort to determine which should be targeted 
therapeutically. Though, in addition to the genetic element of cancer, our 
conception of this multifaceted disease is further confounded by the existence of 
nongenetic factors with roles in tumor progression. For instance, chronic mitogenic 
stimuli have been linked to tumor development, mainly by promoting increased cell 
proliferation177. Moreover, heterotypic interactions between tumor cells and their 
microenvironment are recognized with an increased importance to cancer 
progression178 and inflammatory processes seemingly serve a central role in the 
development of many human cancers161. The discovery of cancer stem cells179,180 
has dramatically changed our views of multistep tumorigenesis as these self-
renewing cells, rather than the bulk population of cancer cells, may be the principal 
objects of genetic alteration and clonal selection that must be targeted in the clinic. 
However, even though the existence of pathological nongenetic factors further 
complicates our understanding of human cancer, they may at the same time provide 
new avenues for treatment of this devastating disease. 
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Populärvetenskaplig sammanfattning 
 
Cancer är den näst vanligaste dödsorsaken i västvärlden och i Sverige upptäckts 
ungefär 50 000 nya fall per år. Cancer är egentligen en grupp av cirka 200 olika 
sjukdomar som främst drabbar äldre personer.  
 
Det är när något går snett i kontrollen över kroppens egna celler som cancer kan 
uppstå. I de flesta cancerformer uppkommer en tumör, en samling förändrade celler 
med förmågan att föröka sig okontrollerat. Ibland kan celler från en sådan tumör 
sprida sig i kroppen och sätta dödliga dottertumörer (metastaser). Man vet idag att 
cancer beror på skador (mutationer) i arvsmassan (DNA). I arvsmassan finns över 
20 000 olika gener som styr de otaliga processer som hela tiden pågår i en cell. Det 
är framförallt gener som har med cellförökning att göra som är muterade i cancer. 
Det räcker dock inte med att endast en gen blir muterad för att cancer skall uppstå 
och man har visat att ett flertal mutationer i olika gener krävs för canceruppkomst.  
 
I denna avhandling har vi undersökt en familj av gener (FET familjen) som är 
muterade i över tio olika cancerformer. Dessa gener förekommer i en speciell form 
i sjukdomarna och hittas som s.k. fusionsgener. En fusionsgen uppkommer när två 
olika gener smälts samman och bildar en ny förändrad gen. Den nya genen består 
nu av delar från båda de två ursprungliga generna (se Figure 1b, sidan 15). De 
fusionsgener där FET gener ingår har skapats genom att två olika kromosomer 
brutits av och felaktigt fogats samman. Specifika FET fusionsgener har endast 
hittats i en eller ett fåtal tumörtyper och man tror att de förändrade generna bidrar 
stort till att just dessa tumörer uppkommer (se Figure 4, sidan 21). Gener utgör 
dock i de flesta fall endast mallar för proteiner, som är de verkliga aktörerna i 
cellen. Det är dessa molekyler som utför de olika livsnödvändiga funktionerna i 
cellen. När FET familjens fusionsgener uppkommer skapas abnorma proteiner som 
tros påverka ett flertal olika processer på cellnivå.  
 
I det första arbetet har vi undersökt de vanliga, oförändrade FET proteinerna (FUS, 
EWS och TAF15) för att förstå vad som kan gå fel när dessa förändras i 
tumörceller. Vi har analyserat FET proteinernas förekomst (uttryck) och 
lokalisering i celler från en mängd olika humana vävnader. Från dessa försök drar 
vi slutsatsen att FET proteinerna visar stor variation i uttryck och lokalisering 
mellan olika celltyper. Detta tros innebära att de har specialiserade funktioner i 
olika celltyper och är involverade i cellers utmognad. Genom experimentella försök 
med odlade celler såg vi även att FET proteinerna verkar vara inblandade dels i 
cellens svarsreaktioner mot inre och yttre stress och dels när celler sprider ut sig på 
ytor. Förändringar i sådana processer är vanligt förekommande hos cancerceller. 
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I det andra arbetet har vi specifikt studerat fusionsproteinet FUS-DDIT3. Detta 
protein hittas endast i tumörformen myxoid liposarkom, en fettcellstumör som 
uppstår i kroppens mjukdelar. Vi har undersökt de molekylära mekanismer varmed 
FUS-DDIT3 påverkar ett flertal av cellens gener. Från dessa försök drar vi 
slutsatsen att FUS-DDIT3 kan felaktigt reglera en viss typ av gener genom att 
samarbeta med NF-κB proteinet NFKBIZ. NF-κB systemet är inblandat i 
inflammationsrelaterade processer och vi drar därför slutsatsen att sådana processer 
kan vara av betydelse för uppkomsten av myxoid liposarkom. 
 
I det tredje arbetet undersöker vi ett protein, FLT1, som fungerar som en mottagare 
för signaler som härstammar från cellens utsida. Sådana signaler kan reglera 
cellförökning och används av kroppen för att hålla antalet celler i en vävnad i 
balans. I många cancerformer är dock dessa signalleringssystem satta ur spel och 
cellerna förökar sig oavsett vilka signaler som kommer utifrån. Oftast uttrycker en 
viss celltyp signalsubstansen och en annan celltyp mottagarproteinet. När vi 
studerade tumörceller som innehåller FUS-DDIT3 proteinet såg vi att dessa 
uttrycker både mottagarproteinet FLT1 och dess signalmolekyl PGF. Vi tror därför 
att dessa celler på så sätt kan stimulera sig själva att bli fler. Blockering av denna 
signalväg skulle därför kunna vara en möjlig väg till behandling av myxoid 
liposarkom. 
 
I det sista arbetet har vi studerat om FUS-DDIT3 proteinet direkt kan påverka 
proteiner som verkar för cellförökning. Vi har funnit att FUS-DDIT3 binder till 
proteinet CDK2, ett protein som är centralt vid cellförökning. Denna inbindning 
verkar påverka CDK2s förmåga att koppla till sig andra proteiner. I nuläget vet vi 
dock inte vilken relevans interaktionen mellan FUS-DDIT3 och CDK2 har för 
tumörutveckling och detta kräver ytterligare studier. 
 
Vi drar slutsatsen att FET fusionsproteinerna, och specifikt FUS-DDIT3, verkar 
kunna påverka en mängd olika kontrollsystem i cellen vilket kan leda till cancer. 
Detta tros vara anledningen till att man inte hittar så många ytterligare 
genförändringar i tumörer med FET fusioner. Vi föreslår även att behandling av 
myxoid liposarkom skulle kunna förbättras genom att använda medel som 
stimulerar cellutmognad, inflammationshämmande läkemedel eller mediciner som 
blockerar FLT1/PGF signalering. 
 
 
 
 
 
 
Se även: Mattias Andersson och Pierre Åman ”Skadade stamceller ger cancer hos 
unga” Forskning och Framsteg nr 7 okt-nov 2005. 
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